THERION RECOMBINANT VACCINIA HIV1 IIIB ENV/GAG/POL VACCINE AND MN RGP120/HIV1

THERION 重组疫苗 HIV1 IIIB ENV/GAG/POL 疫苗和 MN RGP120/HIV1

• 批准号: 6219583
• 负责人: BARNEY S GRAHAM
• 金额: $ 0.06万
• 依托单位: VANDERBILT UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-12-01 至 1999-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6219583
• 关键词: AIDS vaccines; DNA directed DNA polymerase; HIV envelope protein; HIV envelope protein gp120; aluminum; clinical research; clinical trial phase I; drug screening /evaluation; gag protein; human immunodeficiency virus 1; human subject; recombinant virus; vaccinia virus; vector vaccine

Evaluate the safety and immunogenicity of priming with TBC-3B, which consists of live, recombinant vaccinia virus expressing the env and gag/pol genes of HIV-1 strain followed by boosting with HIV-1 recombinant gp120 strain MN vaccine formulated in alum, in healthy HIV-1 uninfected adult voluteers who who have never previously received vaccinia virus. We are currently in the follow up phase of this study.

在从未接受过牛痘病毒感染的健康HIV-1未感染成人志愿者中，评估TBC-3B的安全性和免疫原性，TBC-3B由表达HIV-1株的env和gag/pol基因的重组活痘苗病毒组成，然后用明矾配制的重组HIV-1 gp120株MN疫苗增强。我们目前正处于这项研究的后续阶段。